Enrico Fabris researcher (ORCID 0000-0001-9458-0736)
Fabris, Enrico
VIAF ID: 116864359 (Personal)
Permalink: http://viaf.org/viaf/116864359
Preferred Forms
- 100 0 _ ‡a Enrico Fabris ‡c researcher (ORCID 0000-0001-9458-0736)
- 100 1 _ ‡a Fabris, Enrico
- 100 1 _ ‡a Fabris, Enrico (sparse)
4xx's: Alternate Name Forms (1)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
[Appropriateness and surroundings: "Doing more does not mean doing better". Choosing Wisely, an unfulfilled commitment?] | |
Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial | |
Bilateral coronary obstruction in high-risk transcatheter aortic valve-in-valve implantation: When procedural strategy counts. | |
Bioresorbable vascular scaffold radial expansion and conformation compared to a metallic platform: insights from in vitro expansion in a coronary artery lesion model | |
Bioresorbable vascular scaffold restenosis: intravascular imaging evaluation. | |
Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome | |
Coronary covered stents | |
Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention | |
The evolution of cardiology: changes, future challenges and opportunities | |
Fractional Flow Reserve-Guided Deferred Versus Complete Revascularization in Patients With Diabetes Mellitus | |
Guide extension, unmissable tool in the armamentarium of modern interventional cardiology. A comprehensive review | |
[If heart failure or cardiac arrest complicate pregnancy and delivery] | |
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. | |
Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target? | |
International Subspecialty Fellowship Training, the Path for Cardiologists of Tomorrow?: A European Perspective. | |
Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention | |
Is ischemia the only factor predicting cardiovascular outcomes in all diabetes mellitus patients? | |
Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. | |
One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial | |
Preoperative Intra-Aortic Counterpulsation in Cardiac Surgery: Insights From a Retrospective Series of 588 Consecutive High-Risk Patients. | |
Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction | |
Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial | |
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach | |
Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial | |
[Sudden cardiac death in patients with left ventricular dysfunction from ischemic heart disease: role of the implantable defibrillator. Evidence, guidelines and good clinical judgment] | |
Three-vessel coronary artery disease evaluation by multimodality imaging with near-infrared spectroscopy (NIRS) plus intravascular ultrasound (IVUS) and optical coherence tomography (OCT) | |
Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial. | |
Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis |